We are live on
!
Find out more
EAM
Eventide Asset Management Portfolio holdings
AUM
$6.05B
1-Year Est. Return
76.64%
This Fund
S&P 500
This Quarter
Est. Return
+18.78%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$5.71B
AUM Growth
+$688M
(+14%)
Cap. Flow
-$39.8M
Cap. Flow
% of AUM
-0.7%
Top 10 Holdings %
Top 10 Hldgs %
24.42%
Holding
257
New
40
Increased
127
Reduced
58
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EQT Corp
EQT
|
+$26.6M |
| 2 |
Chewy
CHWY
|
+$26M |
| 3 |
Verisk Analytics
VRSK
|
+$25.3M |
| 4 |
Frontdoor
FTDR
|
+$24.3M |
| 5 |
Lam Research
LRCX
|
+$20.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celldex Therapeutics
CLDX
|
+$46.7M |
| 2 |
Micron Technology
MU
|
+$33.6M |
| 3 |
Snowflake
SNOW
|
+$29.5M |
| 4 |
Inspire Medical Systems
INSP
|
+$21.7M |
| 5 |
Evolent Health
EVH
|
+$18.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.06% |
| 2 | Technology | 18.81% |
| 3 | Industrials | 18.23% |
| 4 | Consumer Discretionary | 7.45% |
| 5 | Utilities | 4.58% |
Similar funds
HPG
EMPI
RCG
WHRC
JWBC
AAM
AA
CM
Eventide Asset Management's Q2 2025 Portfolio in Review
As of Q2 2025, Eventide Asset Management held 257 positions worth $5.71B, up 14% from $5.02B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Eventide Asset Management's Q2 2025 filing shows 40 new, 127 increased, 58 reduced and 20 closed positions. Its largest new stake was Frontdoor: 483,677 shares worth $28.5M. The largest sale was Celldex Therapeutics, an estimated $46.7M.
By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.
- Eventide Asset Management's largest Q2 2025 buy was Frontdoor: 483,677 shares worth $28.5M.
- Eventide Asset Management added most to EQT Corp in Q2 2025, an estimated $26.6M increase.
- Eventide Asset Management's biggest Q2 2025 reduction was Celldex Therapeutics, cutting an estimated $46.7M.
- Eventide Asset Management fully exited Krystal Biotech in Q2 2025, selling an estimated $17.3M.
- Eventide Asset Management's ten largest holdings make up 24% of its $5.71B portfolio in Q2 2025.
- Eventide Asset Management opened 40 new positions and closed 20 in Q2 2025.
- Eventide Asset Management's portfolio value rose 14% quarter-over-quarter to $5.71B.
Based on Eventide Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.